GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

AI and wireless sensing detect five common lung diseases touch-free, enabling early, personalised health monitoring.

China NMPA approves GSK’s Nucala to treat adults with chronic obstructive pulmonary disease: London, UK Tuesday, January 6, 2026, 10:00 Hrs [IST] GSK plc announced that China’ ...

Tv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and ...

A heartbroken daughter has revealed she is "haunted" by the thought of her father's final moments as he struggled for breath ...

As 2026 begins, India’s health sector faces formidable challenges. The main priorities include improving health ...

Experts are warning that 'social smoking'—smoking only at parties or gatherings—also carries significant health risks. According to a New York Times report on the 30th (local time), the medical commun ...

WWE Hall of Famer Jake Roberts has battled health issues in previous years, and now, the legend is set to undergo hip ...

A National Health Service that acts as a safety net for the most vulnerable is under threat, according to recently retired ...

GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils.

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...